Amelotex, tablets 7.5 mg 20 pcs.

Amelotex is a non-steroidal anti-inflammatory drug with anti-inflammatory, antipyretic and analgesic effects.

Indications

Active ingredient

Composition

How to take, the dosage

The drug is taken orally with meals once a day.

The recommended dosing regimen:

The maximum daily dose should not exceed 15 mg.

In patients at increased risk of side effects, and in patients with significant renal impairment who are on hemodialysis, the dose should not exceed 7.5 mg daily.

Interaction

Concomitant use with other nonsteroidal anti-inflammatory drugs (as well as with acetylsalicylic acid) increases the risk of erosive ulcerative lesions and bleeding from the gastrointestinal tract.

In concomitant use with hypotensive drugs, the effectiveness of the latter may be reduced.

Simultaneous use with lithium preparations may lead to cumulation of lithium and increase its toxic effects (it is recommended to control the lithium concentration in the blood).

In concomitant use with methotrexate there is an increased side effect of the latter on the hematopoietic system (risk of anemia and leukopenia, periodic control of total blood count is indicated).

Concomitant use with diuretics and with cyclosporine increases the risk of renal failure.

Concomitant use with intrauterine contraceptives may decrease the effectiveness of the latter.

In concomitant use with anticoagulants (heparin, ticlopidine, warfarin), as well as with thrombolytic drugs (streptokinase, fibrinolysin) the risk of bleeding increases (periodic monitoring of blood clotting is necessary).

In concomitant use with colestiramine, as a result of binding of meloxicam, its excretion through the gastrointestinal tract is increased.

Concomitant use with selective serotonin reuptake inhibitors increases the risk of gastrointestinal bleeding.

Special Instructions

Caution should be exercised when using the drug in patients with a history of peptic ulcer disease and duodenal ulcer, as well as in patients on anticoagulant therapy. These patients have an increased risk of gastrointestinal ulcer-erosive diseases.

Perhaps caution should be exercised and renal function parameters should be monitored when using the drug in elderly patients, patients with chronic heart failure with circulatory insufficiency, patients with cirrhosis of the liver, and patients with hypovolemia due to surgical interventions.

In patients with renal insufficiency, if creatinine clearance is greater than 30 ml/min, no dosing adjustment is necessary. In patients on hemodialysis, the dosage of the drug should not exceed 7.5 mg/day.

In case of persistent and significant elevation of transaminases and changes in other liver function parameters, the drug should be discontinued and control tests should be performed.

Patients taking diuretics and meloxicam at the same time should take plenty of fluids.

If allergic reactions (itching, skin rash, urticaria, photosensitization) occurred during treatment, the drug should be stopped.

Meloxicam, as well as other non-steroidal anti-inflammatory drugs, can mask the symptoms of infectious diseases.

The use of meloxicam, as well as other drugs that block the synthesis of prostaglandins, may affect fertility, so it is not recommended for women planning to become pregnant.

The effect on the ability to drive:

The use of the drug may cause adverse effects in the form of headache and dizziness, drowsiness. It is necessary to refrain from driving vehicles and operating machines and mechanisms requiring concentration.

Contraindications

Side effects

Gastrointestinal tract: more than 1% – dyspepsia, including nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea; 0.1-1% – transient increase in “liver” transaminases activity, hyperbilirubinemia, belching, esophagitis, gastroduodenal ulcer, bleeding from the gastrointestinal tract (including hidden).including latent), stomatitis; less than 0.1% – gastrointestinal perforation, colitis, hepatitis, gastritis.

Hematopoietic organs: more than 1% – anemia; 0.1-1% – changes of blood count, including leukopenia, thrombocytopenia.

The skin: more than 1% – itching, skin rash; 0,1-1% – urticaria; less than 0,1% – photosensitization, bullous rash, erythema multiforme, including Stevens-Johnson syndrome, toxic epidermal necrolysis.

Respiratory system disorders: less than 0.1% – bronchospasm.

Nervous system disorders: more than 1% – dizziness, headache; 0.1-1% – vertigo, tinnitus, drowsiness; less than 0.1% – confusion, disorientation, emotional lability.

Cardiovascular system: more than 1% – peripheral edema; 0.1-1% – increase of blood pressure, palpitation, “rushes” of blood to the face.

Urinary system: 0.1-1% – hypercreatininemia and/or increased serum urea; less than 0.1% – acute renal failure; relationship with meloxicam administration is not determined – interstitial nephritis, albuminuria, hematuria.

Sensory system disorders: less than 0.1% – conjunctivitis, visual impairment, including blurred vision.

Allergic reactions: less than 0.1% – angioedema, anaphylactoid/anaphylactic reactions.

Overdose

Symptoms: impaired consciousness, nausea, vomiting, epigastric pain, gastrointestinal bleeding, acute renal failure, liver failure, respiratory arrest, asystole.

Treatment: there is no specific antidote; in case of overdose of the drug, gastric lavage, administration of activated charcoal (within the next hour), symptomatic therapy should be carried out. Colestiramine accelerates excretion of the drug from the body. Forced diuresis, hemodialysis are ineffective due to high binding of the drug to blood proteins.

Pregnancy use

Similarities